CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 21, 2012
Result type: Reports
Project Number: SR0291-000
Product Line: Reimbursement Review

Generic Name: Ivacaftor

Brand Name: Kalydeco

Manufacturer: Vertex Pharmaceuticals Inc.

Therapeutic Area: Cystic fibrosis, G551D mutation

Indications: Cystic Fibrosis patients (G551D mutation)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: March 22, 2013

Recommendation Type: List with criteria/condition